ReviewPharmaceutics2022
Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 36 citations in OpenAlex.
- [Research square · 2026Article
- Novel Radiotherapy Delivery Modalities and Their Potential to Synergize with Immunotherapy.Biomedicines · 2026Article
- CD8 immunoPET imaging to stratify response and guide combination immunotherapy and radiation in triple negative breast cancer.Breast cancer research : BCR · 2026Article
- Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases.Precision oncology · 2026Article
- Nanocarrier-based intranasal drug delivery for enhanced neurological disorders treatment.Drug delivery and translational research · 2026Review
- Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026Review
- Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice.Nature communications · 2026Article
- Combination therapy of anEuropean journal of nuclear medicine and molecular imaging · 2026Article
- The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy.Military Medical Research · 2026Review
- Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges.Frontiers in pharmacology · 2026Review
- Evaluation of cumulative absorbed dose in tumors of various sizes regardingAnnals of nuclear medicine · 2026Article
- LiposomalCancer science · 2025Article
- Immune modulation following α and βOncoimmunology · 2025Article
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy.Cancer immunology research · 2025Article
- Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025Review
- Review
- Combination of Radioligand Therapy and Immunotherapy: How to Make It Work in Clinic?ImmunoTargets and therapy · 2025Article
- Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors.Radiation (Multidisciplinary Digital Publishing Institute) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention-a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in preclinical studies, whereas results of clinical studies have been mixed. Several clinical trials combining TRT and immune checkpoint blockade have been initiated based on preclinical studies combining these with EBRT and/or TRT. Despite the interest in translation of TRT and immunotherapy combinations, many questions remain surrounding the mechanisms of interaction and the optimal approach to clinical implementation of these combinations. This review highlights the mechanisms of interaction between anti-tumor immunity and radiation therapy and the status of basic and translational research and clinical trials investigating combinations of TRT and immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.